Nuformix (LON:NFX) Posts Earnings Results

Nuformix (LON:NFX) released its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Nuformix Price Performance

Nuformix stock opened at GBX 0.08 ($0.00) on Friday. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of £647,254.90, a P/E ratio of -1.63 and a beta of 1.22. The business has a 50-day moving average of GBX 0.06 and a 200-day moving average of GBX 0.10. Nuformix has a 1 year low of GBX 0.04 ($0.00) and a 1 year high of GBX 0.34 ($0.00).

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.